Start here if you're new
what it is
908 Devices sells handheld and desktop chemical analysis machines that tell you what stuff is, fast, in labs and in the field.
how it gets paid
Last year Devices made $56M in revenue. Handheld chemical analysis devices was the main engine at $33.3M, or 59% of sales.
why it's growing
Revenue grew 17.7% last year. 177% revenue growth matters because a company this small needs bursts of demand to prove its products have real pull.
what just happened
Revenue hit $39M, up 177% vs. prior year, while EPS came in at $0.43.
At a glance
B balance sheet — gets the job done, barely
55/100 earnings predictability — expect surprises
-$1.18 fy2024 eps est
$908M fy2021 rev est
70.1% operating margin
xvary composite: 48/100 — below average
What they do
908 Devices sells handheld and desktop chemical analysis machines that tell you what stuff is, fast, in labs and in the field.
Mass spectrometry → molecular fingerprinting → you get lab-grade chemical ID without waiting on a central lab. That matters when your customer needs answers on the spot, whether it is bioprocessing or hazardous materials. The installed base reached 3,736 devices by Q4 2025, which gives 908 Devices more service revenue and more chances to sell the next box into the same account.
How they make money
$56M
annual revenue · their business grew +17.7% last year
Handheld chemical analysis devices
$33.3M
+21.0%
Desktop bioprocessing and lab devices
$12.9M
+17.7%
Service and contracts
$8.8M
+17.7%
Program product and service
$1.0M
0.0%
The products that matter
portable chemical analysis
Handheld Devices
3,736 devices in the field
This installed base is the core of the story. It supports 35% recurring revenue from service, consumables, and contracts, which is what keeps this from being a pure one-time hardware sale.
installed base
desktop mass spec platform
Viper
40+ units shipped in Q4
Viper shipped over 40 units in Q4 2025 and generated $3M in initial revenue. For a company this size, that is not a side project. It is one of the few numbers that can move the growth case.
new launch
ftir instrumentation
RedWave Products
Q4 revenue +21%
RedWave helped drive 21% Q4 revenue growth from a year ago. That matters because this business needs more than one product line doing the lifting.
growth support
Key numbers
70.1%
operating margin
Operating margin → profit after running the business → so what: 908 Devices still loses about 70 cents for every $1 of sales.
$56M
annual revenue
This is a very small revenue base for a public company, which makes every quarter look bigger, better, worse, and weirder.
$4M
long-term debt
Long-term debt is just 2% of capital, so leverage is low. If this fails, it will be because the business does not scale, not because debt crushes it.
1.7
beta
Beta → how violently a stock moves versus the market → so what: this name tends to swing harder than the index.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $4M (2% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for MASS right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Revenue hit $39M, up 177% vs. prior year, while EPS came in at $0.43.
That quarter looks huge against a $56 million annual revenue base, which tells you lumpiness is part of the story. Gross margin was 49.6%, so the company can make decent hardware margin even while total operating costs stay too high.
$39M
revenue
$0.43
eps
49.6%
gross margin
the number that mattered
177% revenue growth matters because a company this small needs bursts of demand to prove its products have real pull, not just nice demos.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk here is cash burn outrunning commercialization. 908 Devices has enough cash to keep going. It does not have unlimited time to stay unprofitable.
med
cash runway is the thesis buffer
The company has $113M in cash and only about $4M of long-term debt. That looks clean. The catch is that management still frames the cash balance as roughly two years of runway at the current burn pace.
If growth slips before losses narrow, equity dilution becomes a financing event, not a hypothetical.
med
Viper has to become a business, not a headline
Viper shipped 40+ units in Q4 and generated $3M in initial revenue. That is a strong start. It is still early, and early platform launches can look exciting long before they look repeatable.
If Viper stalls, the 15–20% 2026 growth target gets much harder to hit.
med
recurring revenue is helpful, but still only 35%
Recurring revenue gives the model some ballast. It also means roughly 65% of sales are still exposed to placement timing, customer budgets, and contract variability.
That keeps revenue lumpy and makes quarterly misses easier than the story suggests.
med
public safety and government budgets are not fast money
Part of the installed base story depends on first responders and institutional buyers. Those customers can be sticky, but procurement cycles are slow and budget-driven.
With only $64.5M–$67.5M of guided 2026 revenue, even a handful of delayed orders can show up in the numbers.
The combined risk picture is simple: a $227M company with $56M in sales can afford some misses, but not many, when the cash runway is measured in years instead of decades.
source: institutional data · regulatory filings · risk analysis
Pay attention to
trend
Viper follow-through
Q4 shipped 40+ units and produced $3M in revenue. You want to see that become a pattern, not a launch quarter spike.
calendar
Q1 2026 earnings
Expected around May 12, 2026. The key question is whether management keeps the $64.5M–$67.5M full-year guide intact.
metric
recurring mix above 35%
If recurring revenue climbs from 35%, the business gets more predictable. If it stalls, you are still underwriting a lumpy hardware model.
risk
cash balance versus growth pace
$113M in cash sounds comfortable. On a two-year runway, every quarter without better scale or better margins makes that number feel smaller.
Analyst rankings
earnings predictability
55 / 100
Earnings are only moderately predictable. In human-speak, expect uneven quarters and a market that reacts hard to small misses.
beta
1.7
Beta measures how much a stock tends to move versus the market. At 1.7, this usually moves more than the index — up or down.
source: institutional data
Institutional activity
institutional ownership data for MASS is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$7
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive